logo-loader
Arecor

Full interview: Arecor completes dosing in its Phase I clinical trial and secures key partnership

Arecor's Sarah Howell tells Proactive London's Andrew Scott they've now completed dosing and patient visits in the Austria-based phase I study of its ultra-rapid acting insulin candidate, AT247, with results expected by the end of the year.

They've also signed a research, development and commercialisation deal with JDRF - the world's leading type 1 diabetes research charity.

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arecor doses first patient in Phase I trial for ultra-rapid acting insulin...

Dr Sarah Howell, chief executive of Arecor, speaks to Proactive London after announcing the dosing of the first patient in a Phase I clinical trial for its ultra-rapid acting insulin product candidate AT247. AT247 is an ultra-rapid acting product candidate targeting improved treatment for...

on 7/5/19

2 min read